HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Siegel, J. A. Articles by Wahl, R. L. Search for Related Content PubMed PubMed Citation Articles by Siegel, J. A. Articles by Wahl, R. L.

A Practical Methodology for Patient Release After Tositumomab and ¹³¹I-Tositumomab Therapy

¹ Nuclear Physics Enterprises, Cherry Hill, New Jersey
² Corixa Corporation, South San Francisco, California
³ University of Michigan Medical Center, Ann Arbor, Michigan
⁴ Johns Hopkins Medical Institutes, Baltimore, Maryland

A methodology was developed determining patient releasability after radioimmunotherapy with tositumomab and ¹³¹I-tositumomab for the treatment of non-Hodgkin’s lymphoma. Methods: Dosimetry data were obtained and analyzed after 157 administrations of ¹³¹I-tositumomab to 139 patients with relapsed or refractory non-Hodgkin’s lymphoma. Tositumomab and ¹³¹I-tositumomab therapy included dosimetric (low activity) and therapeutic (high activity) administrations. For each patient, the total-body residence time was calculated after the dosimetric administration from total-body counts obtained over 6 or 7 d and was then used to determine the appropriate therapeutic activity to deliver a specific total-body radiation dose. Patient dose rates at 1 m were measured immediately after the therapeutic infusion. Patient-specific calculations based on the measured total-body residence time and dose rate for ¹³¹I-tositumomab were derived to determine the patient’s maximum releasable dose rate at 1 m, estimated radiation dose to maximally exposed individuals, and the amount of time necessary to avoid close contact with others. Results: The mean administered activity (±SD), determined by dosimetry studies for each patient before therapy, was 3,108 ± 1,073 MBq (84 ± 29 mCi) (range, 1,221 ± 5,957 MBq [33–161 mCi]). Immediately after treatment, the mean measured dose rate (±SD) at 1 m was 0.109 ± 0.032 mSv/h (10.9 ± 3.2 mrem/h; range, 0.04–0.24 mSv/h [4–24 mrem/h]). The measured dose rates were 60% (range, 37%–90%; P < 0.0001) of the theoretic dose rates from a point source in air predicted using the dose equivalent rate per unit activity of ¹³¹I (5.95 x 10^-5 mSv/MBq h [0.22 mrem/mCi h] at 1 m). The mean estimated radiation dose to the maximally exposed individual was 3.06 mSv (306 mrem) (range, 1.95–4.96 mSv [195–496 mrem]). On the basis of current regulatory patient-release criteria, all ¹³¹I-tositumomab–treated patients were determined to be releasable by comparing the dose rate at 1 m with a predetermined maximum releasable dose rate. Detailed instructions were provided to limit family members’ exposure. Conclusion: A methodology has been developed for the release of patients administered radioactive materials based on the new Nuclear Regulatory Commission regulations. This approach uses a patient-specific dose calculation based on the measured total-body residence time and dose rate. This analysis shows the feasibility of outpatient radioimmunotherapy with tositumomab and ¹³¹I-tositumomab.

Key Words: dosimetry • non-Hodgkin’s lymphoma • patient release • radioimmunotherapy

This article has been cited by other articles:

				S. A. Gulec and J. A. Siegel Posttherapy Radiation Safety Considerations in Radiomicrosphere Treatment with 90Y-Microspheres J. Nucl. Med., December 1, 2007; 48(12): 2080 - 2086. [Abstract] [Full Text] [PDF]

				W. C. Cole, J. Barrickman, and G. Bloodworth Essential Role of Nuclear Medicine Technology in Tositumomab and 131I-Tositumomab Therapeutic Regimen for Non-Hodgkin's Lymphoma. J. Nucl. Med. Technol., June 1, 2006; 34(2): 67 - 73. [Abstract] [Full Text] [PDF]

				R. M. Sharkey and D. M. Goldenberg Perspectives on Cancer Therapy with Radiolabeled Monoclonal Antibodies J. Nucl. Med., January 1, 2005; 46(1_suppl): 115S - 127S. [Abstract] [Full Text] [PDF]

				J. M. Vose Bexxar(R): Novel Radioimmunotherapy for the Treatment of Low-Grade and Transformed Low-Grade Non-Hodgkin's Lymphoma Oncologist, April 1, 2004; 9(2): 160 - 172. [Abstract] [Full Text] [PDF]

				E. J. Postema, P. K.E. Borjesson, W. C.A.M. Buijs, J. C. Roos, H. A.M. Marres, O. C. Boerman, R. de Bree, M. Lang, G. Munzert, G. A.M.S. van Dongen, et al. Dosimetric Analysis of Radioimmunotherapy with 186Re-Labeled Bivatuzumab in Patients with Head and Neck Cancer J. Nucl. Med., October 1, 2003; 44(10): 1690 - 1699. [Abstract] [Full Text] [PDF]

				B. D. Cheson Radioimmunotherapy of non-Hodgkin lymphomas Blood, January 15, 2003; 101(2): 391 - 398. [Abstract] [Full Text] [PDF]

				J. A. Siegel, C. S. Marcus, and R. B. Sparks Calculating the Absorbed Dose from Radioactive Patients: The Line-Source Versus Point-Source Model J. Nucl. Med., September 1, 2002; 43(9): 1241 - 1244. [Abstract] [Full Text] [PDF]

				E. Lubin Definitive Improvement in the Approach to the Treated Patient as a Radioactive Source J. Nucl. Med., March 1, 2002; 43(3): 364 - 365. [Full Text] [PDF]